Albert DaCosta - Apr 21, 2025 Form 4 Insider Report for Paragon 28, Inc. (FNA)

Signature
/s/ Robert McCormack, as Attorney-in-Fact for Albert DaCosta
Stock symbol
FNA
Transactions as of
Apr 21, 2025
Transactions value $
$0
Form type
4
Date filed
4/21/2025, 05:00 PM
Previous filing
Mar 24, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FNA Common Stock Disposed to Issuer -1.31M -100% 0 Apr 21, 2025 Direct F1, F2, F3
transaction FNA Common Stock Disposed to Issuer -3.28M -100% 0 Apr 21, 2025 See Footnote F1, F2, F4
transaction FNA Common Stock Disposed to Issuer -2.06M -100% 0 Apr 21, 2025 See Footnote F1, F2, F5
transaction FNA Common Stock Disposed to Issuer -5M -100% 0 Apr 21, 2025 See Footnote F1, F2, F6
transaction FNA Common Stock Disposed to Issuer -100K -100% 0 Apr 21, 2025 By Spouse F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FNA Performance Stock Unit Disposed to Issuer -234K -100% 0 Apr 21, 2025 Common Stock 234K Direct F1, F3
transaction FNA Stock Option (Right to Buy) Disposed to Issuer -75K -100% 0 Apr 21, 2025 Common Stock 75K $0.60 Direct F1, F7
transaction FNA Stock Option (Right to Buy) Disposed to Issuer -125K -100% 0 Apr 21, 2025 Common Stock 125K $1.20 Direct F1, F7
transaction FNA Stock Option (Right to Buy) Disposed to Issuer -125K -100% 0 Apr 21, 2025 Common Stock 125K $4.60 Direct F1, F7
transaction FNA Stock Option (Right to Buy) Disposed to Issuer -50K -100% 0 Apr 21, 2025 Common Stock 50K $5.40 Direct F1, F7
transaction FNA Stock Option (Right to Buy) Disposed to Issuer -37.5K -100% 0 Apr 21, 2025 Common Stock 37.5K $6.60 Direct F1, F7
transaction FNA Stock Option (Right to Buy) Disposed to Issuer -75K -100% 0 Apr 21, 2025 Common Stock 75K $6.60 Direct F1, F7
transaction FNA Stock Option (Right to Buy) Disposed to Issuer -451K -100% 0 Apr 21, 2025 Common Stock 451K $16.00 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Albert DaCosta is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 In connection with the terms of an Agreement and Plan of Merger, dated January 28, 2025 (the "Merger Agreement"), by and among the Issuer, Zimmer Biomet Holdings, Inc., Zimmer, Inc. ("Parent"), and Gazelle Merger Sub I, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time").
F2 At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $13.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $1.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent, Equiniti Trust Company, LLC, as rights agent, and, for certain provisions, Zimmer Biomet Holdings, Inc., as guarantor.
F3 At the Effective Time, each outstanding (i) restricted stock unit ("RSU") solely subject to time-based vesting conditions and (ii) RSU subject to both performance-based and time-based vesting conditions ("PSU") vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award (with the PSUs vesting at 140% of the target number of shares of Common Stock subject to such PSUs), (x) the Cash Consideration and (y) one CVR.
F4 Shares are held by The DaCosta Family Trust, of which the Reporting Person is trustee.
F5 Shares are held by trusts for the benefit of the Reporting Person's children, of which the Reporting Person is trustee.
F6 Shares are held by DaCosta Investment Company, LLC, of which the Reporting Person is a manager.
F7 At the Effective Time, each outstanding option vested and was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such option, (i) an amount in cash equal to the excess, if any, of the Cash Consideration over the per share exercise price of such option and (ii) one CVR. Notwithstanding the foregoing, (a) any option with a per share exercise price equal to or greater than the sum of the Cash Consideration and the maximum milestone payment amount pursuant to the CVR Agreement was canceled for no consideration and (b) any option with a per share exercise price that is equal to or greater than the Cash Consideration but less than the sum of the Cash Consideration and the maximum milestone payment amount pursuant to the CVR Agreement was converted into the right to receive one CVR with respect to each share of Common Stock underlying such option, subject to the terms of the CVR Agreement.

Remarks:

President & Chief Executive Officer